Remove 2027 Remove Patients Remove Prescription
article thumbnail

How to Successfully Market Your GLP-1 Program: Strategies for Standing Out

LEVO Health

billion by 2027. To stand out in this competitive landscape, businesses must focus on patient engagement, comprehensive service offerings, strong marketing and branding, and strategic partnerships with top-tier telehealth service providers like WellSync and medical marketing experts like Levo Health.

article thumbnail

Specialty Treatments Require a New Approach to Affordability

PM360

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. Figure 1: Share of net spending for specialty and traditional prescription medications. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. However, the impact of the new law will reverberate in the industry for years to come.

article thumbnail

Pharma’s pain from the Inflation Reduction Act will be felt well beyond the first 10 brands facing price cuts

Clarivate

1: CMS obtained steep price cuts in its first round of negotiations Source: The Centers for Medicare & Medicaid Services By 2027, 20 additional drugs per year will be negotiated, including often complex and expensive physician-administered Medicare Part B drugs, such as infusible biologics.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. RxPass offers more than 50 select prescriptions at no additional cost for $5 per month.

Retail 52
article thumbnail

Industry Briefs December 2022

PM360

In its latest venture into the healthcare arena, Amazon is reaching out directly to the consumer via its soon-to-be-launched Amazon Clinic , a virtual health service for patients to see licensed clinicians about common medical issues. billion euros into its new facility where it is planning to hire 400 and 500 new personal by 2027.